Abstract
Prophylaxis with palivizumab has been shown to decrease hospitalizations in at-risk infants. Compliance was higher with a home-based rather than a clinic-based system and was associated with decreased hospitalizations and unscheduled medical visits. Home-based delivery of respiratory syncytial virus prophylaxis may be more efficacious in preventing disease through increased compliance and decreased exposure of the high-risk infant to the clinic environment.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Female
-
Humans
-
Infant
-
Male
-
Palivizumab
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Retrospective Studies
-
Risk Factors
-
Urban Population
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Palivizumab